<DOC>
	<DOCNO>NCT01110083</DOCNO>
	<brief_summary>EMD Serono close enrollment trial prior determination maximum tolerate dose ( MTD ) . EMD Serono decide pursue development EMD 1204831 patient advance solid tumor reason safety .</brief_summary>
	<brief_title>First-in-Man , Dose-escalation Trial c-Met Kinase Inhibitor EMD 1204831 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>This open-label , dose-escalation , first-in-man ( FIM ) study design explore safety , tolerability , pharmacokinetics , clinical activity investigational drug , EMD 1204831 , patient advance solid tumor respond previous therapy therapy available . Subjects receive EMD 1204831 twice day ( BID ) 21-day cycle disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Main Inclusion Criteria 1 . Histologically cytologically confirm solid tumor , either refractory standard therapy effective standard therapy available 2 . Measurable evaluable disease , define RECIST 1.0 3 . Men woman age ≥ 18 year 4 . ECOG performance status 0 2 5 . Adequate hematological function : Hemoglobin ≥ 9.0 g/dL ; Neutrophils &gt; 1.5 x 109/L ; Platelets ≥ 100 x 109/L 6 . Adequate liver function : Total bilirubin ≤ 1.5 x ULN ; AST/ ALT ≤ 2.5 x ULN 7 . For subject liver metastasis : Total bilirubin ≤ 1.5 x ULN ; AST/ALT ≤ 5 ULN 8 . Adequate renal function : Serum creatinine &lt; 1.5 x ULN , and/or Calculated creatinine clearance &gt; 60 mL/min 9 . Resolution acute chemotherapy , radiotherapy surgeryrelated AEs Grade ≤1 , except alopecia 10 . Recovery surgical intervention 11 . Subjects enrol MTD determine must present specific cMet alteration ( overexpression , amplification , mutation ) Main Exclusion Criteria 1 . Received chemotherapy , immunotherapy , hormonal therapy ( except subject prostate cancer ) , biologic therapy , investigational agent anticancer therapy within 28 day ( five halflives noncytotoxics , whichever short ) , Day 1 trial treatment ( six week nitrosureas mitomycin C ) 2 . Received extensive prior radiotherapy 30 % bone marrow 3 . Symptomatic primary tumor metastasis brain and/or central nervous system , uncontrolled antiepileptic require high dos steroids 4 . Medical history liver fibrosis/ cirrhosis 5 . Medical history surgery within six week prior enrollment 6 . Neuropathy Grade ≥ 2 7 . Requires concurrent treatment nonpermitted drug 8 . Absence abnormal pupillary reflex</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>refractory standard therapy</keyword>
	<keyword>Patients solid tumor , either refractory standard therapy effective standard therapy available</keyword>
</DOC>